当前位置: X-MOL 学术Eur. Heart J. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Cardiac mortality, adequate power, and objective inclusion of the entire evidence are key to accurately define the long-term effect of revascularisation vs. medical therapy alone in stable coronary syndromes
European Heart Journal ( IF 39.3 ) Pub Date : 2021-09-21 , DOI: 10.1093/eurheartj/ehab677
Eliano P Navarese 1, 2, 3 , Felicita Andreotti 4, 5
Affiliation  

This commentary refers to ‘Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis’, by E.P. Navarese et al., doi:10.1093/eurheartj/ehab246; ‘When a meta-analysis equals a single large-scale trial with meaningful follow-up’, by E.P. Navarese et al., doi:10.1093/eurheartj/ehab460; and the discussion pieces ‘Cardiac death should be the primary endpoint for revascularisation trials and meta analyses’, by H.D. White, doi:10.1093/eurheartj/ehab676; ‘In the pool: dilution or drowning?’, by V. Dayan et al., doi:10.1093/eurheartj/ehab443.

中文翻译:

心脏死亡率、足够的功效和客观纳入整个证据是准确定义血运重建与单独药物治疗在稳定型冠状动脉综合征中的长期效果的关键

该评论指的是“随机接受选择性冠状动脉血运重建加药物治疗或单独药物治疗的患者的心脏死亡率:系统评价和荟萃分析”,由 EP Navarese等人撰写, doi:10.1093/eurheartj/ehab246; EP Navarese等人撰写的“当荟萃分析等同于具有有意义随访的单个大规模试验时” , doi:10.1093/eurheartj/ehab460; 以及 HD White 的讨论文章“心脏死亡应该是血运重建试验和荟萃分析的主要终点”,doi:10.1093/eurheartj/ehab676;“在游泳池里:稀释还是淹死?”,作者 V. Dayan等人。, doi:10.1093/eurheartj/ehab443。
更新日期:2021-09-21
down
wechat
bug